Jacqueline C. Barrientos, MD

Articles

Noncovalent BTK Inhibitors in CLL

March 7th 2022

Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

Exciting Results Ignite in Multiple Myeloma and CLL at ASH 2021: Perspectives From Drs Nina Shah and Jacqueline Barrientos

December 12th 2021

OncLive® speaks with Dr. Nina Shah on some practice-changing multiple myeloma abstracts, and Dr. Jacqueline Barrientos on the latest in chronic lymphocytic leukemia.

Dr. Barrientos Discusses Promising Agents in CLL

April 1st 2019

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses promising agents in the treatment of patients with chronic lymphocytic leukemia.

Dr. Barrientos on Important Considerations for Patients with MCL

September 10th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses important considerations for patients with mantle cell lymphoma.

Dr. Barrientos on Advances in the Treatment Landscape for Patients With CLL

August 8th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses advances in the treatment landscape for patients with chronic lymphocytic leukemia (CLL).

Dr. Barrientos Discusses Acalabrutinib in CLL

March 29th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the role of acalabrutinib (Calquence) for patients with chronic lymphocytic leukemia (CLL).

Dr. Barrientos on the Impact of Combinations in CLL

March 15th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the impact of combinations in the treatment of chronic lymphocytic leukemia.

Dr. Barrientos Discusses Combination Strategies in CLL

February 20th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the impact of recent combination trials for patients with chronic lymphocytic leukemia (CLL).

Dr. Barrientos on the Role of Acalabrutinib in CLL

January 26th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the role of acalabrutinib (Calquence) for patients with chronic lymphocytic leukemia (CLL).

CLL in the Era of Targeted Therapies

December 12th 2017

Over the past few years, remarkable advances have been achieved in the field of chronic lymphocytic leukemia by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival.

Dr. Barrientos Discusses Ibrutinib in Elderly Populations With CLL

December 6th 2017

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses ibrutinib (Imbruvica) in elderly populations with CLL.

Dr. Barrientos Discusses the Management of Elderly Patients with CLL

November 14th 2017

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, discusses the management of elderly patients with chronic lymphocytic leukemia (CLL).